2. Search Result
Search Result
Results for "

blood cholesterol

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

1

Screening Libraries

5

Biochemical Assay Reagents

1

Peptides

2

Inhibitory Antibodies

11

Natural
Products

3

Isotope-Labeled Compounds

5

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112490
    Atorvastatin calcium hydrate
    Maximum Cited Publications
    65 Publications Verification

    		 HMG-CoA Reductase (HMGCR) Cardiovascular Disease Others
    Atorvastatin calcium salt trihydrate is a drug belonging to the statin class of drugs used to lower blood cholesterol levels. Atorvastatin calcium salt trihydrate has unique chemical properties that make it an effective tool in controlling high levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the body, reducing the risk of heart attack and stroke. Atorvastatin calcium salt trihydrate works by inhibiting HMG-CoA reductase, the enzyme responsible for producing cholesterol in the liver.
    Atorvastatin calcium hydrate
  • HY-N4103
    Fucosterol
    2 Publications Verification

    		 PARP Endogenous Metabolite Metabolic Disease Cancer
    Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research .
    Fucosterol
  • HY-P9928
    Alirocumab
    1 Publications Verification

    REGN 727; SAR 236553

    		 PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1 Cardiovascular Disease Cancer
    Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .
    Alirocumab
  • HY-124489
    2-Hydroxyestradiol
    2 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity .
    2-Hydroxyestradiol
  • HY-N0466
    Rebaudioside A

    		Glycosidase HMG-CoA Reductase (HMGCR) Fatty Acid Synthase (FASN) LDLR Others
    Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC50 value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity .
    Rebaudioside A
  • HY-W020012
    Fluoresterol

    22-NBD cholesterol

    		 Fluorescent Dye Metabolic Disease
    Fluoresterol (22-NBD Cholesterol) is a cholesterol-specific fluorescent probe with cholesterol-mimicking binding properties. Fluoresterol is ineffective orally and does not cross the blood-brain barrier. Fluoresterol specifically binds to cholesterol transport-related proteins (such as ABCA1 and ABCG1) and is primarily used in cholesterol metabolism research, particularly for the visualization and quantitative analysis of cholesterol absorption, efflux, intracellular transport efficiency, and reverse cholesterol transport (RCT) processes. The commonly used concentration of Fluoresterol in in vitro experiments is 0.1-10 μM, and the commonly used dose in in vivo experiments is 5-20 mg/kg (gavage or intraperitoneal injection), with excitation/emission wavelengths of 472/540 nm. Fluoresterol can be applied to the study of cholesterol metabolism mechanisms related to hyperlipidemia, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD) .
    Fluoresterol
  • HY-108750
    Soybean oil
    1 Publications Verification

    VT 18 (oil); Vegetoil; Wesson

    		 Environmental Pollutants Cardiovascular Disease
    Soybean oil (VT 18 (oil); Vegetoil; Wesson) is an edible vegetable oil. Soybean oil reduces circulating blood cholesterol levels when it replaces dietary saturated fats. Soybean oil does not affect inflammatory biomarkers or increase oxidative stress. Soybean oil contains γ-tocopherol and δ-tocopherol, which possess antioxidant properties. Soybean oil can be used in research related to coronary heart disease .
    Soybean oil
  • HY-P9928A
    Alirocumab (anti-PCSK9)
    1 Publications Verification

    REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)

    		 PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1 Cardiovascular Disease Cancer
    Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .
    Alirocumab (anti-PCSK9)
  • HY-W015780
    1,4-Dimethoxybenzene

    		Environmental Pollutants Endogenous Metabolite Metabolic Disease
    1,4-Dimethoxybenzene is an endogenous metabolite. 1,4-Dimethoxybenzene has an anti-anxiety effect, increasing atherogenic index (AI) levels in rabbits and inducing sedentary behavior. Sedentary behavior may increase blood cholesterol levels and disrupt blood lipids . 1,4-Dimethoxybenzene considers to be not clastogenic in the in vivo micronucleus test .
    1,4-Dimethoxybenzene
  • HY-P10551
    ApoA-I mimetic peptide 5A

    		Transmembrane Glycoprotein NF-κB TNF Receptor Cardiovascular Disease
    ApoA-I mimetic peptide 5A is a synthetic peptide molecule designed based on the structure and function of naturally occurring apolipoprotein A-I (Apo A-I). ApoA-I mimetic peptide 5A can promote the efflux of cholesterol from cells and help reduce the accumulation of cholesterol in cells. ApoA-I mimetic peptide 5A also shows anti-inflammatory activity and can reduce inflammatory markers in blood and tissues. ApoA-I mimetic peptide 5A can be used in the study of cardiovascular diseases .
    ApoA-I mimetic peptide 5A
  • HY-N3807
    Enniatin B1
    1 Publications Verification

    		 Acyltransferase ERK NF-κB Infection Cardiovascular Disease Cancer
    Enniatin B1 is a Fusarium mycotoxin. Enniatin B1 inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 73 μM in an enzyme assay using rat liver microsomes . Enniatin B1 crosss the blood-brain barrier . Enniatin B1 decreases the activation of ERK (p44/p42). Enniatin B1 inhibits moderately TNF-α-induced NF-κB activation .
    Enniatin B1
  • HY-142989
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine

    		Liposome HIV HCV HBV Infection Cancer
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that serves as a component of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs), which are composed of 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol and l-α-phosphatidylserine at a molar ratio of 1.5:1.5:1:1. PERLs reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and decrease HIV-1 particle secretion from HIV-1-infected PBMCs. Liposomes formed from 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine exhibit cytotoxicity against leukemia cells. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is applicable to studies related to hepatitis C virus infection, HIV infection, hepatitis B virus infection and leukemia .
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine
  • HY-W010031
    1-Methyluric acid

    		Drug Metabolite Endogenous Metabolite Metabolic Disease
    1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels.
    1-Methyluric acid
  • HY-W134326
    Polydextrose

    		Bacterial Infection Cardiovascular Disease Metabolic Disease
    Polydextrose is an orally active prebiotic. Polydextrose promotes the growth of Pediococcus pentosaceus ATCC 43200. Polydextrose reduces cholesterol and synergistically lowers blood sugar with Sitagliptin (HY-13749). Currently, it is mainly used in the research of diseases such as hyperlipidemia, type 2 diabetes, and postoperative iron deficiency anemia .
    Polydextrose
  • HY-N0857
    Deoxyandrographolide
    1 Publications Verification

    		 GLUT HDAC Virus Protease PI3K AMPK Akt Histone Demethylase MDM-2/p53 IFNAR Reactive Oxygen Species (ROS) Infection Metabolic Disease Inflammation/Immunology
    Deoxyandrographolide is an orally active lactone found in the Andrographis paniculata Nees. Deoxyandrographolide shows a KD of 38.4 μM of HDAC1. Deoxyandrographolide enhances GLUT4 plasma membrane translocation, activates PI3K and AMPK-dependent signaling pathways, suppresses fasting blood glucose, serum insulin, triglycerides, and LDL-cholesterol levels. Deoxyandrographolide enhances HDAC1 expression via inhibited ubiquitination degradation, represses H3K4me3, improves chromosome stability, and restrains aging biomarkers p16, p21, γH2A.X, p53 and ROS production. Deoxyandrographolide interacts with Foot-and-Mouth Disease Virus 3Cpro active site, inhibits protease and IFN-antagonist activity, derepresses ISG expression, and inhibits viral replication. Deoxyandrographolide can be used for the researches of type 2 diabetes mellitus, vascular senescence and virus infection .
    Deoxyandrographolide
  • HY-121795
    Pravastatin lactone

    		HMG-CoA Reductase (HMGCR) Cardiovascular Disease
    Pravastatin lactone is a potent HMG-CoA inhibitor. Pravastatin Lactone is a metabolite of pravastatin. Pravastatin lactone reduces blood cholesterol levels by inhibiting cholesterol synthesis .
    Pravastatin lactone
  • HY-14921
    Elsibucol

    		Integrin Transmembrane Glycoprotein Cardiovascular Disease Inflammation/Immunology
    Elsibucol is a VCAM1 inhibitor for the study of organ transplant rejection. Elsibucol is a metabolically stable propanol derivative with antioxidant, anti-inflammatory and anti-proliferative properties. Elsibucol lowers blood cholesterol levels and reduces oxidative stress and inflammatory responses in injured arteries, thereby inhibiting atherosclerosis and protecting endothelial healing after arterial injury .
    Elsibucol
  • HY-W010934
    3β,5α,6β-Trihydroxycholestane

    		Biochemical Assay Reagents Others
    3β,5α,6β-Trihydroxycholestane is a steroid that occurs naturally in the body and is also found in certain foods. It belongs to a class of compounds known as cholestanes, which are closely related to the better known cholesterol. This particular compound is formed from cholesterol through a series of enzymatic reactions in the liver and other organs. It has been studied for its potential health benefits, including its ability to reduce inflammation and oxidative stress in the body. Some research suggests that it may also play a role in regulating blood sugar levels and improving insulin sensitivity. Despite these potential benefits, 3β,5α,6β-Trihydroxycholestane is not widely used as a supplement or medicine due to its relatively low content, focus on natural resources and limited research. However, researchers continue to investigate its potential uses and effects on human health.
    3β,5α,6β-Trihydroxycholestane
  • HY-144309
    Cholesterol 24-hydroxylase-IN-1

    		Cytochrome P450 Neurological Disease
    Cholesterol 24-hydroxylase-IN-1 (compound 17) is a potent, orally active, and highly selective cholesterol 24-hydroxylase (CH24H or CYP46A1) inhibitor (IC50=8.5 nM). Cholesterol 24-hydroxylase-IN-1 can cross blood-brain barrier .
    Cholesterol 24-hydroxylase-IN-1
  • HY-107965
    Safflower oil (from Carthamus tinctorius seed)

    Safflower seed oil (from Carthamus tinctorius seed)

    		 Biochemical Assay Reagents Elastase Inflammation/Immunology
    Safflower oil (from Carthamus tinctorius seed) is rich in unsaturated fatty acids such as linoleic acid and oleic acid, as well as tocopherols and phenolic compounds, and exhibits antioxidant, anti-aging and blood lipid-regulating effects. Safflower oil (from Carthamus tinctorius seed) inhibits the activities of collagenase and elastase, and exerts antioxidant activity by scavenging free radicals. Linoleic acid in safflower oil (from Carthamus tinctorius seed) reduces blood cholesterol levels. Safflower oil (from Carthamus tinctorius seed) can be applied to research in fields such as skin aging, atherosclerosis, edible oil processing and industrial raw material development .
    Safflower oil (from Carthamus tinctorius seed)
  • HY-129982
    SC-435

    		Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .
    SC-435
  • HY-148626
    CVI-LM001

    		PCSK9 Metabolic Disease
    CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .
    CVI-LM001
  • HY-N4103R
    Fucosterol (Standard)

    		Reference Standards PARP Endogenous Metabolite Metabolic Disease Cancer
    Fucosterol (Standard) is the analytical standard of Fucosterol. This product is intended for research and analytical applications. Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research .
    Fucosterol (Standard)
  • HY-U00340
    PPAR agonist 1

    		PPAR Metabolic Disease
    PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.
    PPAR agonist 1
  • HY-W709553
    Glyceryl Triformate
    1 Publications Verification

    Triglyceride

    		 Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    Glyceryl Triformate (Triglyceride) is the major form of storage and transport of fatty acids within cells and in the plasma. Glyceryl Triformate forms lipoproteins with cholesterol ester, and participates in the blood circulation. Glyceryl Triformate can lead to hypertriglyceridemia (HTG), which increases the risk of atherosclerotic cardiovascular disease (ASCVD) and pancreatitis .
    Glyceryl Triformate
  • HY-N0466R
    Rebaudioside A (Standard)

    		Reference Standards Glycosidase HMG-CoA Reductase (HMGCR) Fatty Acid Synthase (FASN) LDLR Others
    Rebaudioside A (Standard) is the analytical standard of Rebaudioside A. This product is intended for research and analytical applications. Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC50 value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity.
    Rebaudioside A (Standard)
  • HY-162637
    CTL26

    		Glycosidase Metabolic Disease
    CTL26 is a potent and orally active α-glucosidase inhibitor with an IC50 value of 2.81 µM. CTL26 shows anti-diabetic efficacy .
    CTL26
  • HY-124489R
    2-Hydroxyestradiol (Standard)

    		Endogenous Metabolite Reference Standards Metabolic Disease
    2-Hydroxyestradiol (Standard) is the analytical standard of 2-Hydroxyestradiol. This product is intended for research and analytical applications. 2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity .
    2-Hydroxyestradiol (Standard)
  • HY-116150
    Xymedon

    		Others Cardiovascular Disease
    Xymedon is a pyrimidine derivative with anti-atherosclerotic effects. Xymedon reducts plasma cholesterol levels and cholesterol esterification in blood vascular cells .
    Xymedon
  • HY-153451
    PCSK9-IN-15

    		PCSK9 Metabolic Disease
    PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, KD <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia .
    PCSK9-IN-15
  • HY-115434
    3,5-Diiodothyroacetic acid

    		Thyroid Hormone Receptor Metabolic Disease
    3,5-Diiodothyroacetic acid is a thyroid hormone analog. 3,5-Diiodothyroacetic acid lowers blood cholesterol concentrations. 3,5-Diiodothyroacetic acid can be used for hypothyroidism diseases research .
    3,5-Diiodothyroacetic acid
  • HY-W010031S1
    1-Methyluric acid-d3

    		Isotope-Labeled Compounds Metabolic Disease
    1-Methyluric acid-d3 is the deuterium labeled 1-Methyluric acid (HY-W010031). 1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels .
    1-Methyluric acid-d3
  • HY-117459
    E-3030 free acid

    		PPAR Metabolic Disease
    E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.
    E-3030 free acid
  • HY-B1209R
    Etofylline (Standard)

    7-(β-Hydroxyethyl)theophylline (Standard)

    		 Phosphodiesterase (PDE) Reference Standards Cardiovascular Disease
    Etofylline (Standard) is the analytical standard of Etofylline. This product is intended for research and analytical applications. Etofylline (7-(β-Hydroxyethyl)theophylline) is a N-7-substituted derivative of Theophylline. Etofylline is a bronchodilator which can be used for the research of asthma. Etofylline is also an anticholesteremic and reduces total cholesterol level in the blood .
    Etofylline (Standard)
  • HY-158160
    LBA-3

    		Sodium Channel Metabolic Disease
    LBA-3 is a selective, orally active inhibitor for sodium-coupled citrate transporter SLC13A5, with an IC50 of 67 nM. LBA-3 decreases levels of triglyceride and total cholesterol in oleic and palmitic acid (OPA)-stimulated AML12 cells, PCN-stimulated primary mouse hepatocytes and in mouse models, without detectable toxicity. LBA-3 is blood-brain barrier permeable .
    LBA-3
  • HY-146398
    AMPK activator 6

    		AMPK Metabolic Disease
    AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .
    AMPK activator 6
  • HY-19242
    MX-68

    		Antifolate Inflammation/Immunology
    MX-68 is an orally active antifolate agent. MX-68 can prolong the lifespan of MRL/lpr mice, delay the onset of proteinuria, and inhibit the elevation of serum blood urea nitrogen and cholesterol levels. MX-68 is also an anti-rheumatic agent, which exerts potent antiproliferative effects on rheumatoid arthritis-related cells and can inhibit arthritis in rats. MX-68 can be used in the research of autoimmune diseases such as autoimmune kidney disease and rheumatoid arthritis .
    MX-68
  • HY-114834
    AHL-157

    		Drug Derivative Metabolic Disease
    AHL-157 is a fibrate hypolipidemic agent. AHL-157 can decrease triglyceride, cholesterol, and blood sugar. AHL-157 can be used for the research of metabolic disease, such as hyperlipidemia and diabete .
    AHL-157
  • HY-W010031S
    1-Methyluric acid-13C4,15N3

    		Endogenous Metabolite Metabolic Disease
    1-Methyluric acid- 13C4, 15N3 is the 13C and 15N labeled 1-Methyluric acid . 1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels .
    1-Methyluric acid-13C4,15N3
  • HY-N18732
    Terminalia arjuna extract

    		Others Cardiovascular Disease
    Terminalia arjuna extract is a precious natural compound derived from the bark of the Terminalia arjuna tree, rich in bioactive components such as triterpenoids, flavonoids, tannins, and polyphenols. Terminalia arjuna extract has cardioprotective effects, helping to strengthen the heart muscle, lower cholesterol levels, stabilize blood pressure, and prevent thrombosis.
    Terminalia arjuna extract
  • HY-174332
    Cholesterol 24-hydroxylase-IN-3

    		Cytochrome P450 Neurological Disease
    Cholesterol 24-hydroxylase-IN-3 is an orally active, selective, and blood-brain barrier-penetrant CH24H inhibitor (IC50 = 23 nM) belonging to 1,3-oxazole derivatives. Cholesterol 24-hydroxylase-IN-3 competitively inhibits CH24H enzyme activity by using the 1,3-oxazole nitrogen atom to coordinate the heme iron and the cyclopropyl group occupying the hydrophobic pocket. Cholesterol 24-hydroxylase-IN-3 can be used for research on epilepsy and other neurological diseases.
    Cholesterol 24-hydroxylase-IN-3
  • HY-W343043
    Pyrazinoylguanidine

    PZG

    		 Drug Derivative Cardiovascular Disease Metabolic Disease
    Pyrazinoylguanidine (PZG) is an analogue of the potassium sparing diuretic, Amiloride (HY-B0285). Pyrazinoylguanidine can lower the systolic and diastolic blood pressure of patients with primary hypertension, has a certain effect on reducing heart rate, and does not affect the concentrations of electrolytes such as sodium, potassium, and chloride in the blood serum. Pyrazinoylguanidine can reduce the hyperglycemia and hyperinsulinemia in type 2 diabetes, reduce the levels of triglycerides, cholesterol, and free fatty acids, and reverse the hyperglycemia and hyperlipidemia induced by thiazide diuretics, such as Hydrochlorothiazide (HY-B0252). Pyrazinoylguanidine ican nhibit the reabsorption of urea by the renal tubules, thereby increasing the clearance rate and excretion volume of urea, reducing the serum urea concentration, and minimizing its toxic accumulation .
    Pyrazinoylguanidine
  • HY-N3807S
    Enniatin B1-13C34

    		Isotope-Labeled Compounds Acyltransferase ERK NF-κB Infection
    Enniatin B1- 13C34 is the 13C-labeled Enniatin B1 (HY-N3807). Enniatin B1 is a Fusarium mycotoxin. Enniatin B1 inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 73 μM in an enzyme assay using rat liver microsomes . Enniatin B1 crosss the blood-brain barrier . Enniatin B1 decreases the activation of ERK (p44/p42). Enniatin B1 inhibits moderately TNF-α-induced NF-κB activation .
    Enniatin B1-13C34

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: